Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503856 | 0.90 | ALOX15 (0.81) | ALOX15 | |
| SCHEMBL29954955 | 0.90 | ALOX15 (0.81) | ALOX15 | |
| SCHEMBL9260498 | 0.87 | ALOX15 (0.77) | ALOX15 | |
| SCHEMBL29955715 | 0.85 | ALOX15 (0.74) | ALOX15 | |
| SCHEMBL28640836 | 0.85 | ALOX15 (0.73) | ALOX15 | |
| SCHEMBL29954264 | 0.85 | ALOX15 (0.73) | ALOX15 | |
| SCHEMBL29955347 | 0.85 | ALOX15 (0.73) | ALOX15 | |
| SCHEMBL3029308 | 0.84 | ALOX15 (0.74) | ALOX15 | |
| SCHEMBL4042096 | 0.84 | ALOX15 (0.74) | ALOX15 | |
| SCHEMBL9253578 | 0.84 | ALOX15 (0.72) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103228644-B | 4-Substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-06-01 | — | — | CN | disclosed |
| US-9187441-B2 | p53-Mdm2 antagonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187441-B2 | p53-Mdm2 antagonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2015-11-17 | — | — | US | disclosed |
| US-8921559-B2 | 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-30 | — | — | US | disclosed |
| EP-2646429-B1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2646429-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2013-10-09 | — | — | EP | disclosed |
| US-20130211079-A1 | SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER | DOEMLING ALEXANDER (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130211079-A1 | SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER | DOEMLING ALEXANDER (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130211079-A1 | SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER | DOEMLING ALEXANDER (US) | 2013-08-15 | — | — | US | disclosed |
| US-20120142733-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-07 | — | — | US | disclosed |
| WO-2007006688-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| US-5929248-A | Substituted heteroarylphenyloxazolidinones | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| US-5756732-A | Substituted heteroarylphenyloxazolidinones | PHARMACIA & UPJOHN COMPANY (US) | 1998-05-26 | — | — | US | disclosed |
| US-5654435-A | BACTERICIDES | PHARMACIA & UPJOHN COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| US-5654428-A | BACTERICIDES | PHARMACIA & UPJOHN COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0610265-B1 | SUBSTITUTED ARYL- AND HETEROARYLPHENYLOXAZOLIDINONES USEFUL AS ANTIBACTERIAL AGENTS | UPJOHN CO (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5565571-A | BACTERICIDES | THE UPJOHN COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0610265-A1 | SUBSTITUTED ARYL- AND HETEROARYLPHENYLOXAZOLIDINONES USEFUL AS ANTIBACTERIAL AGENTS. | UPJOHN CO (US) | 1994-08-17 | — | — | EP | disclosed |
| WO-1993009103-A1 | SUBSTITUTED ARYL- AND HETEROARYLPHENYLOXAZOLIDINONES USEFUL AS ANTIBACTERIAL AGENTS | THE UPJOHN COMPANY (US) | 1993-05-13 | — | — | WO | disclosed |
| US-5182367-A | 5-lipoxygenase activating protein | MERCK & CO., INC. (US) | 1993-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211079-A1 | SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER | TP53, MDM4, MDM2 | ALOX15 3298/4885 |
| US-20120142733-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | CCR2, CCR5, CCR1 | ALOX15 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.